SCHEMBL15517575

SCHEMBL15517575

COC(=O)COc1ccccc1-c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ LMNA P02545 3/20 0.55
▸ NOTUM Q6P988 3/20 0.51
▸ ADRA1D P25100 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ ADRA1B P35368 1/20 0.50
▸ AR P10275 1/20 0.49
▸ TDP1 Q9NUW8 3/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ KCNN4 O15554 1/20 0.47
▸ CYP11B1 P15538 1/20 0.47
▸ CYP11B2 P19099 1/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.47
▸ MKNK2 Q9HBH9 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ USP2 O75604 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14327977 0.85 L3MBTL1 (0.64) ALDH1A1LMNAARTDP1L3MBTL1
SCHEMBL18528827 0.84 LMNA (0.58) ALDH1A1LMNAADRA1DADRA1AADRA1B
SCHEMBL15517510 0.82 LMNA (0.60) ALDH1A1LMNANOTUMADRA1DADRA1A
SCHEMBL23646289 0.79 ADRA1D (0.57) ALDH1A1ADRA1DADRA1AADRA1BCYP11B1
SCHEMBL2555729 0.77 KCNA5 (0.51) ALDH1A1CYP11B1CYP11B2MKNK1MKNK2
SCHEMBL14967298 0.77 AR (0.54) ALDH1A1LMNAARTDP1L3MBTL1
SCHEMBL8137336 0.77 POLB (0.64) ALDH1A1ADRA1DADRA1AADRA1BCYP11B1
SCHEMBL15517755 0.77 CYP19A1 (0.52) ALDH1A1NOTUMCYP11B1CYP11B2MKNK1
SCHEMBL28760328 0.77 ADRA1D (0.54) ALDH1A1ADRA1DADRA1AADRA1BCYP11B1
SCHEMBL10506317 0.77 SMN1; SMN2 (0.60) ALDH1A1LMNAL3MBTL1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890677-B1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-11-15 — — EP disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 — — US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 — — US disclosed
EP-2890677-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG Chong Kun Dang Pharmaceutical Corp. (KR) 2015-07-08 — — EP disclosed
WO-2014035149-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG MALT1, MCL1, ACIN1 ALDH1A1 769/4885LMNA 3057/4885NOTUM 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback